Neuropeptides and the immune system: Focus on dendritic cells

Critical Reviews in Immunology

Volumn 21, Issue 6, 2001, Pages 523-557

  Dunzendorfer, Stefan ^a   Wiedermann, Christian J ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Antigen presenting cells; Immunomodulation; Neurogenic inflammation; Neuropeptide receptors; Peripheral neuropeptides

Indexed keywords

ADRENERGIC RECEPTOR; ALPHA INTERMEDIN; BETA ENDORPHIN; CALCITONIN GENE RELATED PEPTIDE; CATECHOLAMINE; CORTICOTROPIN; ENKEPHALIN; HELODERMIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 1; NEUROKININ A; NEUROKININ B; NEUROMEDIN U; NEUROPEPTIDE; NEUROPEPTIDE GAMMA; NEUROPEPTIDE K; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROTENSIN; NEUROTRANSMITTER; OPIATE PEPTIDE; OXYTOCIN; SECRETONEURIN; SUBSTANCE P; TACHYKININ; TACHYKININ RECEPTOR; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPRESSIN;

CELL MIGRATION; DENDRITIC CELL; GENE; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOMODULATION; LANGERHANS CELL; NERVOUS SYSTEM; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; THYMUS; ANIMAL; IMMUNOLOGY;

ANIMAL; DENDRITIC CELLS; HUMAN; IMMUNE SYSTEM; NEUROPEPTIDES; ANIMALS; HUMANS;

EID: 0035545164     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (351)

1. Modulation of immune cell function by the autonomic nervous system
2. In vivo maturation and migration of dendritic cells
3. Chemokines and dendritic cell traffic
4. Dendritic cell based therapy of cancer
5. Immunotherapy of cancer with dendritic-cell-based vaccines
6. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
7. Phenotypic characterization of dendritic cells
8. On the development of psychoneuroimmunology
9. Interactions of neuromediators and neurohormones on dendritic cells, monocytes and macrophages (out of the central nervous system)
10. It's time for psychoneuroimmunology
11. A complete regulatory loop between the immune and neuroendocrine systems
12. The macrophage response to central and peripheral nerve injury. A possible role for macrophages in regeneration
13. Neuroimmunology
14. Neuropeptides and their receptors in the immune system
15. Cytokine-induced sickness behavior: Where do we stand?
16. Neuropeptides and classic innervation: Neural structures in human airways
17. Neurogenic inflammation in airways and its modulation
18. Neurogenic inflammation in the respiratory tract: Actions of sensory nerve mediators on blood vessels and epithelium of the airway mucosa
19. Sensory neuropeptides and airway function
20. Asthma as an axon reflex
21. Sensory nerves, neuropeptides, and asthma
22. Cholinergic signals to and from the immune system
23. Noradrenergic and peptidergic innervation of lymphoid tissue
24. Catechol-O-methyltransferase activity and aminergic binding sites distribution in human peripheral blood lymphocyte subpopulations
25. Neuropeptide Y inhibits in vivo specific antibody production in rats
26. Molecular cloning of NPY-Y1 receptor cDNA from rat splenic lymphocytes: Evidence of low levels of mRNA expression and [125I]NPY binding sites
27. Effect of neuropeptide Y on natural killer activity of normal human lymphocytes
28. Physiology and pharmacology of corticotropin-releasing factor
29. Cellular interactions in thymocyte development
30. Neuroendocrine control of thymus physiology
31. The concept of neurogenic inflammation in the respiratory tract
32. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin
33. The role of sensory nerve endings in neurogenic inflammation induced in human skin and in the eye and paw of the rat
34. Glial activation: A driving force for pathological pain
35. Neuropeptides as regulators of airway function: Vasoactive intestinal peptide and the tachykinins
36. Mammalian tachykinin receptors
37. A regulatory neuropeptide for hematopoiesis and immune functions
38. Amino-acid sequence of substance P
39. Substance P precursor and kininogen: Their structures, gene organizations, and regulation
40. Tachykinins
41. Substance P: A pioneer amongst neuropeptides
42. Principles of tachykininergic co-transmission in the peripheral and enteric nervous system
43. Effect of substance P on cardiovascular and respiratory function in subjects
44. Comparison of neurokinin A and substance P on cardiovascular and airway function in man
45. Effect of inhaled substance P and neurokinin A on the airways of normal and asthmatic subjects
46. Tachykinins in the gut. Part I. Expression, release and motor function
47. Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation
48. Substance P: Localization in the central nervous system and in some primary sensory neurons
49. Release of substance P from the spinal dorsal horn is enhanced in polyarthritic rats
50. Release of immunoreactive substance P in the spinal cord during development of acute arthritis in the knee joint of the cat: A study with antibody microprobes
51. Cutaneous stimuli releasing immunoreactive substance P in the dorsal horn of the cat
52. Novel substance P antagonist, CP-96,345, blocks responses of cat spinal dorsal horn neurons to noxious cutaneous stimulation and to substance P
53. The nonpeptide NK-1 receptor antagonists LY303870 and LY306740 block the responses of spinal dorsal horn neurons to substance P and to peripheral noxious stimuli
54. Injury-induced plasticity of spinal reflex activity: NK1 neurokinin receptor activation and enhanc
55. Neurokinin A-like immunoreactivity in rat primary sensory neurons; coexistence with substance P
56. Effects of substance P on functionally identified units in cat spinal cord
57. The involvement of neurokinin receptor subtypes in somatosensory processing in the superficial dorsal horn of the cat
58. Intrathecal neurokinin A facilitates the spinal nociceptive flexor reflex evoked by thermal and mechanical stimuli and synergistically interacts with substance P
59. The differential roles of substance P and neurokinin A in spinal cord hyperexcitability and neurogenic inflammation
60. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing
61. Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species
62. Galanin-like immunoreactivity in capsaicin sensitive sensory neurons and ganglia
63. Impaired IL-1beta-induced neutrophil accumulation in tachykinin NK1 receptor knockout mice
64. Neurokinin-1 receptors are involved in behavioral responses to high-intensity heat stimuli and capsaicin-induced hyperalgesia in mice
65. Neuromedin U-8 and U-25, novel uterus stimulating and hypertensive peptides identified in porcine spinal cord
66. Characterization of the rat uterine neuromedin U receptor
67. Isolation, structural characterization, and bioactivity of a novel neuromedin U analog from the defensive skin secretion of the Australasian tree frog, Litoria caerulea
68. Cloning and characterization of the cDNA encoding the human neuromedin U (NmU) precursor: NmU expression in the human gastrointestinal tract
69. Primary structure of neuromedin U from the rat
70. Isolation and structural determination of rat neuromedin U
71. The distribution, purification, and pharmacological action of an amphibian neuromedin U
72. Isolation and microsequence analysis of a novel form of neuromedin U from guinea pig small intestine
73. Rabbit neuromedin U-25, lack of conservation of a posttranslational processing site
74. Isolation, structural characterization and pharmacological activity of dog neuromedin U
75. The purification and sequence analysis of an avian neuromedin U
76. Effects of neuromedin U-8 on the secretory activity of the rat adrenal cortex: Evidence for an indirect action requiring the presence of the zona medullaris
77. Effects of neuromedin U (NMU)-8 on the rat hypothalamo-pituitary-adrenal axis. Evidence of a direct effect of NMU-8 on the adrenal gland
78. Role of neuromedins in the regulation of adrenocortical function
79. Neuromedins: Novel smooth-muscle stimulating peptides identified in porcine spinal cord
80. Effect of synthetic neuromedin U-8 and U-25, novel peptides identified in porcine spinal cord, on splanchnic circulation in dogs
81. Regional hemodynamic effects of neuromedin U in conscious rats
82. Neuromedin U octapeptide alters ion transport in porcine jejunum
83. Immunocytochemical localization of endogenous codeine and morphine
84. Bioactive peptides in anterior pituitary cells
85. Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications
86. Bacterial lipopolysaccharide induction of leukocyte-derived corticotropin and endorphins
87. Newcastle disease virus-infected splenocytes express the proopiomelanocortin gene
88. Localization of enkephalins and other endogenous opioids in the digestive tract
89. Cholecystokinin/opioid interactions
90. Endomorphins: Novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor density
91. Relationship between exposure to stress and development of hypertension
92. Characterization of receptor types for neuropeptide Y and related peptides
93. Evolution of the neuropeptide Y family of peptides
94. Cloning, characterization, and DNA sequence of a human cDNA encoding neuropeptide tyrosine
95. C-terminal neuropeptide Y fragments are mast cell-dependent vasodepressor agents
96. Molecular structure of mammalian neuropeptide Y: Analysis by molecular cloning and computer-aided comparison with crystal structure of avian homologue
97. Transient expression of neuropeptide Y and its C-flanking peptide immunoreactivities in the spinal cord and ganglia of human embryos and fetuses
98. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system-II. Immunohistochemical analysis
99. Organization of neuropeptide Y neurons in the mammalian central nervous system
100. Neuropeptide Y-related peptides and their receptors - Are the receptors potential therapeutic drug targets?
101. PP, PYY and NPY-occurrence and distribution in the periphery
102. Neuropeptide Y (NPY) in the area of the hypothalamic paraventricular nucleus activates the pituitary-adrenocortical axis in the rat
103. Neuropeptide Y administration acutely increases hypothalamic corticotropin-releasing factor immunoreactivity: Lack of effect in other rat brain regions
104. Neuropeptide-Y stimulates CRF-41 release from rat hypothalami in vitro
105. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells
106. Evolution of the growth hormone-releasing factor (GRF) family of peptides
107. The glucagon-like peptides
108. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38)
109. Expression and alternative processing of a chicken gene encoding both growth hormone-releasing hormone and pituitary adenylate cyclase-activating polypeptide
110. Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene
111. Growth hormone-releasing hormone: Synthesis and signaling
112. Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: Immunocytochemical and immunochemical evidence
113. Pituitary adenylate cyclase activating peptide produces a marked and long-lasting depression of a C-fibre-evoked flexion reflex
114. Messenger plasticity in primary sensory neurons following axotomy and its functional implications
115. Expression of pituitary adenylate cyclase-activating polypeptide in dorsal root ganglia following axotomy: Time course and coexistence
116. Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide
117. Polypeptide with broad biological activity: Isolation from small intestine
118. Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome
119. The gene encoding vasoactive intestinal peptide is located on human chromosome 6p21-6qter
120. Regulation of VIP gene expression in general. Human lung cancer cells in particular
121. Binding of sequence-specific proteins to the 3′-untranslated region of vasoactive intestinal peptide mRNA
122. Alternatively polyadenylated vasoactive intestinal peptide mRNAs are differentially regulated at the level of stability
123. VIP: Molecular biology and neurobiological function
124. The complete structure of the rat VIP gene
125. High conservation of upstream regulatory sequences on the human and mouse vasoactive intestinal peptide (VIP) genes
126. STAT proteins are activated by ciliary neurotrophic factor in cells of central nervous system origin
127. Cholinergic and vasoactive intestinal polypeptidergic innervation of the cerebral arteries
128. Vasoactive intestinal polypeptide and other preprovasoactive intestinal polypeptide-derived peptides in the female and male genital tract: Localization, biosynthesis, and functional and clinical significance
129. Modulation of immune function by intestinal neuropeptides
130. Roles of peptides in enteric neuromuscular transmission
131. Primary structure and characterization of the precursor to human pituitary adenylate cyclase activating polypeptide
132. Pharmacological characterization of VIP receptors in human lung membranes
133. Secretoneurin: A functional neuropeptide in health and disease
134. A determination of the solution conformation of secretoneurin, a neuropeptide originating from the processing of secretogranin II, by 1H-NMR and restrained molecular dynamics
135. Ontogenic development of secretogranin II and of its processing to secretoneurin in rat brain
136. Formation and sequence analysis of secretoneurin, a neuropeptide derived from secretogranin II, in mammalian, bird, reptile, amphibian and fish brains
137. The neuroendocrine proteins secretogranin II and III are regionally conserved and coordinately expressed with proopiomelanocortin in Xenopus intermediate pituitary
138. Distribution of secretoneurin, a peptide derived from secretogranin II, in rat brain: An immunocytochemical and radioimmunological study
139. Distribution of secretoneurin-like immunoreactivity in comparison with substan
140. Distribution of secretoneurin immunoreactivity in the spinal cord and lower brainstem in comparison with that of substance P and calcitonin gene-related peptide
141. Evidence for a high density of secretoneurin-like immunoreactivity in the extended amygdala of the rat
142. Human and rat primary C-fibre afferents store and release secretoneurin, a novel neuropeptide
143. Secretoneurin-like immunoreactivity in rat sympathetic, enteric and sensory ganglia
144. Immunohistochemical detection of secretoneurin, a novel neuropeptide endoproteolytically processed from secretogranin II, in normal human endocrine and neuronal tissues
145. Secretoneurin: A new peptide in the human enteric nervous system
146. Secretoneurin, a novel neuropeptide, in the human dental pulp
147. Secretoneurin. A novel carotid body peptide
148. Presence and distribution of a new neuropeptide, secretoneurin, in human retina
149. Attraction of human monocytes by the neuropeptide secretoneurin
150. Secretoneurin, a novel neuropeptide, is a potent chemoattractant for human eosinophils
151. Deactivation of chemotaxis of human neutrophils by priming with secretogranin II-derived secretoneurin
152. Stimulation of human skin fibroblast migration by the neuropeptide secretoneurin
153. Staurosporine-dependent activation of human endothelial cell monolayers for neutrophil adherence by secretoneurin
154. Calcitonin gene-related peptide in the nervous tissue
155. Pharmacology of receptors for calcitonin gene-related peptide and amylin
156. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products
157. Isolation and characterization of human calcitonin gene-related peptide
158. Alternative RNA processing: Determining neuronal phenotype
159. Evolutionary pathways of the calcitonin genes
160. Cell-specific glucocorticoid repression of calcitonin/calcitonin gene-related peptide transcription. Localization to an 18-base pair basal enhancer element
161. Stimulation of calcitonin/CGRP-I and CGRP-II gene expression by dibutyryl cAMP in a human medullary thyroid carcinoma (TT) cell line
162. Distribution of neurons expressing calcitonin gene-related peptide mRNAs in the brain stem, spinal cord and dorsal root ganglia of rat and guinea-pig
163. Colchicine enhances mRNAs encoding the precursor of calcitonin gene-related peptide in brainstem motoneurons
164. Primary sensory neurons of the rat showing calcitonin generelated peptide immunoreactivity and their relation to substance P, somatostatin-, galanin-, vasoactive intestinal polypep
165. Peptides and the primary afferent nociceptor
166. Pathway-specific patterns of the co-existence of substance P, calcitonin gene-related peptide, cholecystokinin and dynorphin in neurons of the dorsal root ganglia of the guinea-pig
167. Ultrastructural studies on peptides in the dorsal horn of the spinal cord-I. Co-existence of galanin with other peptides in primary afferents in normal rats
168. Ultrastructural evidence for the coexistence of calcitonin gene-related peptide and substance P in secretory vesicles of peripheral nerves in the guinea pig
169. Calcitonin gene-related peptide and cerebral blood vessels: Distribution and vasomotor effects
170. Peptide-containing nerve fibers in human cerebral arteries: Immunocytochemistry, radioimmunoassay, and in vitro pharmacology
171. Calcitonin gene-related peptide (CGRP) in capsaicinsensitive substance P-immunoreactive sensory neurons in animals and man: Distribution and release by capsaicin
172. Calcitonin gene-related peptide: Functional role in cerebrovascular regulation
173. Calcitonin gene-related peptide in cardiovascular tissues of the rat
174. Calcitonin gene-related peptide is a potent vasodilator
175. Regional hemodynamic effects of calcitonin gene-related peptide
176. Calcitonin gene-related peptide: Potent vasodilator and major product of calcitonin gene
177. Human and rat alpha-CGRP but not calcitonin cause mesenteric vasodilatation in rats
178. Human calcitonin gene related peptide: A potent endogenous vasodilator in man
179. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability
180. The effects of calcitonin gene-related peptide on formation of intra-articular oedema by inflammatory mediators
181. A calcitonin generelated peptide (CGRP) antagonist (CGRP8-37) inhibits microvascular responses induced by CGRP and capsaicin in skin
182. Calcitonin gene-related peptide inhibits interleukin 2 production by murine T lymphocytes
183. Modulation of B lymphocyte differentiation by calcitonin gene-related peptide (CGRP). I. Characterization of high-affinity CGRP receptors on murine 70Z/3 cells
184. Calcitonin gene-related peptide (CGRP) activates human neutrophils-inhibition by chemotactic peptide antagonist BOC-MLP
185. Proopiomelanocortin-derived peptides in the immune system
186. Alpha-Melanocyte stimulating hormone in the modulation of host reactions
187. Anti-inflammatory effects of the neuropeptide alpha-MSH in acute, chronic, and systemic inflammation
188. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH
189. Antimicrobial effects of alpha-MSH peptides
190. Alpha-MSH production, receptors, and influence on neopterin in a human monocyte/macrophage cell line
191. A potential mechanism of local anti-inflammatory action of alpha-melanocyte-stimulating hormone within the brain: Modulation of tumor necrosis factor-alpha production by human astrocytic cells
192. Production of immunosuppressing melanotropins by human keratinocytes
193. The neuropeptide alpha-MSH in HIV infection and other disorders in humans
194. Resuscitating effect of melanocortin peptides after prolonged respiratory arrest
195. The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats
196. alpha-MSH modulates experimental inflammatory bowel disease
197. alpha-MSH modulates local and circulating tumor necrosis factor-alpha in experimental brain inflammation
198. Animals under the sun: Effects of ultraviolet radiation on mammalian skin
199. alpha-MSH and the regulation of melanocyte function
200. Endotoxin causes release of alpha-melanocyte-stimulating hormone in normal human subjects
201. Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy
202. Plasma concentrations of alpha-melanocyte-stimulating hormone are elevated in patients on chronic haemodialysis
203. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami
204. Neurotensin: Peptide for the next millennium
205. Does neurotensin mediate the effects of antipsychotic drugs?
206. The neurobiology of neurotensin: Focus on neurotensin-dopamine interactions
207. Central administration of neurotensin stimulates hypothalamic-pituitary-adrenal activity. The paraventricular CRF neuron as a critical site of action
208. Blockade of neurotensin binding in the rat hypothalamus and of the central action of neurotensin on the hypothalamic-pituitary-adrenal axis with non-peptide receptor antagonists
209. The effect of thyroid hormones in vitro and in vivo on hypothalamic neurotensin release and content
210. Effects of prolonged administration of neurotensin, arginine-vasopressin, NPY, and bombesin on blood TSH, T3 and T4 levels in the rat
211. Increased glucose production following neurotensin administration
212. Neurotensin activates tuberoinfundibular dopamine neurons and increases serum corticosterone concentrations in the rat
213. Multiple peptides infrequently coexist in progester-one receptor-containing neurons in the ventrolateral hypothalamic nucleus of the guinea-pig: An immunocytochemical triple-label analysis of somatostatin, neurotensin and substance P
214. Neuroimmune mechanisms of intestinal responses to stress. Role of corticotropin-releasing factor and neurotensin
215. Identification of neurotensin-related peptides in human thymic epithelial cell membranes and relationship with major histocompatibility complex class I molecules
216. Towards a molecular understanding of dendritic cell immunobiology
217. Dendritic cells and the control of immunity
218. Immunobiology of dendritic cells
219. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha
220. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor alpha
221. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking
222. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand
223. Expression of pTalpha mRNA in a committed dendritic cell precursor in the human thymus
224. Modulating the immune response with dendritic cells and their growth factors
225. The dendritic cell system and its role in immunogenicity
226. Maturation and migration of cutaneous dendritic cells
227. Origin and steady-state turnover of class II MHC-bearing dendritic cells in the epithelium of the conducting airways
228. Dendritic cells: Unique leukocyte populations which control the primary immune response
229. The cell biology of antigen presentation in dendritic cells
230. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization
231. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation
232. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways
233. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis
234. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
235. alphavbeta5 integrin recruits the CrkII-Dock180-rac1 complex for phagocytosis of apoptotic cells
236. Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo
237. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
238. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses
239. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules
240. Intracellular pathway for the generation of functional MHC class II peptide complexes in immature human dendritic cells
241. The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules
242. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells
243. Developmental regulation of MHC class II transport in mouse dendritic cells
244. Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells
245. Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation
246. Langerhans cells require signals from both tumour necrosis factor alpha and interleukin 1 beta for migration
247. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels
248. Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin
249. CC chemokine receptor (CCR)2 is required for langerhans cell migration and localization of T helper cell type 1 (Th1)-inducing dendritic cells. Absence of CCR2 shifts the Leishmania major-resistant phenotype to a susceptible state dominated by Th2 cytokines, b cell outgrowth, and sustained neutrophilic inflammation
250. Enhanced epidermal Langerhans cell migration in IL-10 knockout mice
251. Interaction of dendritic cells with skin endothelium: A new perspective on immunosurveillance
252. Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3alpha, MIP-3beta, and secondary lymphoid organ chemokine
253. Endotoxin-mediated dendritic cell release from the intestine. Characterization of released dendritic cells and TNF dependence
254. Rapid dendritic cell recruitment is a hallmark of the acute inflammatory response at mucosal surfaces
255. Endothelial-like cells derived from human CD14 positive monocytes
256. Dendritic cells: On the move from bench to bedside
257. Dendritic cell vaccines for cancer immunotherapy
258. Vaccination of melanoma patients with pep
259. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
260. Dendritic cells in cancer immunotherapy
261. Pulmonary response to inhaled antigen: Neuroimmune interactions promote the recruitment of dendritic cells to the lung and the cellular immune response to inhaled antigen
262. Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide
263. Close anatomical relationships between nerve fibers and MHC class II-expressing dendritic cells in the rat liver and extrahepatic bile duct
264. Developmental pathways of human myeloid dendritic cells
265. Maturation of human monocyte-derived dendritic cells studied by microarray hybridization
266. Identification of a human gastrointestinal tract and immune system receptor for the peptide neuromedin U
267. Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation
268. Thy-1+ dendritic cells express truncated form of POMC mRNA
269. Localization of calcitonin gene-related peptide in human esophageal Langerhans cells
270. Colocalization of somatost
271. Tachykinin receptors and tachykinin receptor antagonists
272. Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells
273. The tachykinin family of peptides and their receptors
274. Binding and in vitro modulation of human epidermal Langerhans cell functions by substance P
275. Effect of UVB 311 nm irradiation on normal human skin
276. Expression of neurotrophic factors and neuropeptide receptors by Langerhans cells and the Langerhans cell-like cell line XS52, further support for a functional relationship between Langerhans cells and epidermal nerves
277. Expression of authentic substance P receptors in murine and human dendritic cells
278. Multiple receptors for PACAP and VIP
279. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide
280. The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide
281. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor
282. The effect of neuropeptides/hormones on Langerhans cells
283. Vasoactive intestinal peptide synergizes with TNF-alpha in inducing human dendritic cell maturation
284. Cutting edge: Peripheral neuropeptides attract immature and arrest mature blood-derived dendritic cells
285. Identification of an orphan receptor gene as a type 1 calcitonin gene-related peptide receptor
286. Cloning and expression of cDNA encoding a rat adrenomedullin receptor
287. hCGRP8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery
288. Characterization of CGRP1 and CGRP2 receptor subtypes
289. Photoaffinity labeling of rat calcitonin gene-related peptide receptors and adenylate cyclase activation: Identification of receptor subtypes
290. Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues. Evidence for receptor multiplicity
291. A cDNA encoding the calcitonin gene-related peptide type 1 receptor
292. Calcitonin gene-related peptide decreases expression of HLA-DR and CD86 by human dendritic cells and dampens dendritic cell-driven T cell-proliferative responses via the type I calcitonin gene-related peptide receptor
293. Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide: Relevance to functional effects
294. The cloning of a family of genes that encode the melanocortin receptors
295. Receptor biology of the melanocortins, a family of neuroimmunomodulatory peptides
296. The central melanocortin system and energy homeostasis
297. Evidence for the differential expression of the functional alpha-melanocyte-stimulating hormone receptor MC-1 on human monocytes
298. alpha-MSH and its receptors in regulation of tumor necrosis factor-alpha production by human monocyte/macrophages
299. The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro
300. Human peripheral blood-derived dendritic cells express functional melanocortin receptor MC-1R
301. alpha-melanocyte-stimulating hormone as a mediator of tolerance induction
302. NF-kappa B: Ten years after
303. Specific binding of a 125I-secretoneurin analogue to a human monocytic cell line
304. Secretoneurin and chemoattractant receptor interactions
305. Expression of gastrin-releasing peptide receptor in human skin
306. Murine dendritic cells express functional delta-type opioid receptors
307. Hapten-specific tolerance promoted by calcitonin gene-related peptide
308. Substance P binds to the formylpeptide chemotaxis receptor on the rabbit neutrophil
309. Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines
310. Activation of human monocytes via a non-neurokinin substance P receptor that is coupled to Gi protein, calcium, phospholipase D, MAP kinase, and IL-6 production
311. Substance P activates NF-kappaB independent of elevations in intracellular calcium in murine macrophages and dendritic cells
312. Regulation of cytosolic free Ca2+ in cultured rat alveolar macrophages (NR8383)
313. The role of alpha-MSH as a modulator of cutaneous inflammation
314. Pro-opiomelanocortin-derived peptides induce IL-10 production in human monocytes
315. Antipyretic role of endogenous melanocortins mediated by central melanocortin receptors during endotoxin-induced fever
316. Regulation of dendritic cell trafficking: A process that involves the participation of selective chemokines
317. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites
318. Morphologic and histochemical evidence for the occurrence of collagenolysis and for the role of neutrophilic polymorphonuclear leukocytes during cervical dilation
319. Cervical ripening as an inflammatory reaction
320. Neurogenic inflammation caused by cutaneous polymodal receptors
321. Neurochemical and cellular markers in human cervix of late pregnant, postpartal and non-pregnant women
322. Langerhans cell migration
323. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro
324. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells
325. Mice deficient in IL-1beta manifest impaired contact hypersensitivity to trinitrochlorobenzone
326. IL-4 inhibits the migration of human Langerhans cells through the downregulation of TNF receptor II expression
327. Interleukin-1 receptor antagonist suppresses contact hypersensitivity
328. Influence of sodium lauryl sulphate on 2,4-dinitrochlorobenzene-induced lymph node activation
329. Role of tumour necrosis factor-alpha in ultraviolet B light-induced dendritic cell migration and suppression of contact hypersensitivity
330. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization
331. Epidermal denervation and its effects on keratinocytes and Langerhans cells
332. Langerhans cells in the neuro-immunocutaneous system
333. Neuropeptides and Langerhans cells
334. Expression of neuropeptides on human epidermal Langerhans cells
335. Expression of somatostatin on Langerhans cells
336. Reduction of the DTH response is related to morphological changes of Langerhans cells in mice exposed to acute immobilization stress
337. Regulation of cytokine expression in macrophages and the Langerhans cell-like line XS52 by calcitonin gene-related peptide
338. Alpha-melanocyte stimulating hormone modulates contact hypersensitivity responsiveness in C57/BL6 mice
339. Beta-endorphin binding and regulation of cytokine expression in Langerhans cells
340. Calcitonin gene-related peptide and Langerhans cell function
341. Calcitonin gene-related peptide is necessary for ultraviolet B-impaired induction of contact hypersensitivity
342. Calcitonin gene-related peptide and nitric oxide are involved in ultra-violet radiation-induced immunosuppression
343. A substance p agonist acts as an adjuvant to promote hapten-specific skin immunity
344. Neuropeptide Y-like immunoreactivity in Langerhans cells from patients with atopic dermatitis
345. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism
346. Proteinase-activated receptors: Novel mechanisms of signaling by serine proteases
347. Protease activated receptors: Theme and variations